Original Articles: InterventionsSafety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old
Section snippets
INTRODUCTION
Allergic rhinitis (AR) is the most common chronic disease in children.1, 2 It is estimated to affect up to 40% of children in the United States,1 and the incidence of the disease is increasing in children worldwide.3, 4, 5 The symptoms of AR may appear in infancy, with the diagnosis generally established by the age of 6 years. Poorly controlled AR may lead to onset or exacerbation of comorbid conditions, such as asthma, sinusitis, respiratory infections, nasal polyps, otitis media, and/or
Study participants
Approximately 500 male and female children with AR aged 2 to 5 years were to be enrolled and equally distributed across the age groups. The diagnosis of AR was supported by previous medical history and 1 or more of the following physical signs: clear nasal discharge, swelling and/or changes in color of turbinates, or cobblestoning (ie, dimpled appearance).
Children were excluded if they had clinically relevant abnormalities or medical conditions that could interfere with the study (eg, severe
Study participants
The baseline characteristics of the study population are presented in Table 1. A total of 453 children were enrolled at 30 study sites (fexofenadine, n = 222; placebo, n = 231). No significant differences were found in the demographics across groups. A total of 180 fexofenadine-treated children and 178 placebo-treated children completed the study; children were considered to have completed the study if treatment duration was 12 days or more and they had ingested 22.5 doses or more (80% of the
DISCUSSION
Fexofenadine hydrochloride, 30 mg twice daily, was well tolerated, with a good safety profile, in children aged 2 to 5 years with AR in this study. In a population pharmacokinetic analysis, a 30-mg dose of fexofenadine hydrochloride in children aged 1 to 12 years and weighing more than 10.5 kg produced similar exposures to that of a 60-mg dose in adults. This finding suggests that fexofenadine hydrochloride, 30 mg, may be an appropriate dose for children aged 2 to 5 years and validates the
ACKNOWLEDGMENTS
We thank the study investigators and, in addition, Lesley Brewer, BSc (Hons), Medicus International, for her editorial assistance with the manuscript. Editorial assistance was funded by sanofi-aventis US Inc.
REFERENCES (24)
Pediatric allergic rhinitis and comorbid disorders
J Allergy Clin Immunol
(2001)Overview of comorbid associations of allergic rhinitis
J Allergy Clin Immunol
(1997)Quality of life in adults and children with allergic rhinitis
J Allergy Clin Immunol
(2001)- et al.
Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials
J Allergy Clin Immunol
(1994) - et al.
Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis
Ann Allergy Asthma Immunol
(1999) - et al.
First do no harm: managing antihistamine impairment in patients with allergic rhinitis
J Allergy Clin Immunol
(2003) - et al.
Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 mg and 180 mg once-daily) and cetirizine in seasonal allergic rhinitis
J Allergy Clin Immunol
(1999) - et al.
Safety of fexofenadine in children treated for seasonal allergic rhinitis
Ann Allergy Asthma Immunol
(2001) - et al.
Fexofenadine is efficacious and safe in children (aged 6–11 years) with seasonal allergic rhinitis
J Allergy Clin Immunol
(2003) - US Department of Health and Human Services, Agency for Healthcare Research and Quality. Management of allergic and...
Allergic rhinitis
Asthma and allergic rhinitis among Finnish adolescents in 1977–1991
Scand J Soc Med
Cited by (0)
Dr Milgrom is on the speaker's bureau for Novartis and Genentech and has received funding support from Novartis, GlaxoSmithKline, AstraZeneca, and sanofi-aventis. Dr Lanier is on the speaker's bureau for Alcon Laboratories, Schering Laboratories, and Sanofi; is an investigator for Alcon Laboratories, Schering Laboratories, Sanofi, and Genentech; and is a consultant for Alcon Laboratories and Schering Laboratories. Dr Hampel has received, during the last 2 years, research support from the following companies: Alcon Research Ltd, Allux Medical, Altana Pharma, Amphastar Pharmaceuticals Inc, Apotex Inc, Boehringer-Ingelheim, Collegium, Dynavax, Emergent Biosolutions, GlaxoSmithKline, Inspire Pharmaceuticals Inc, MAP Pharmaceuticals Inc, MedImmune Inc, MedPointe Pharmaceuticals, Merck Research Laboratories, Morton Grove Pharmaceuticals, Novartis Pharmaceuticals, Pharmaxis Ltd, Sankyo Pharma Development, sanofi-aventis, Schering-Plough, Sepracor Inc, SkyePharma, and SUN Pharmaceuticals. Dr Kittner is a full-time employee of sanofi-aventis US Inc.
Financial support for this study was provided by sanofi-aventis US Inc.